Skip to main content
. Author manuscript; available in PMC: 2017 Mar 1.
Published in final edited form as: Eur Urol. 2015 May 13;69(3):505–511. doi: 10.1016/j.eururo.2015.04.028

Table 2.

Discrimination of total prostate-specific antigen

High-grade cancer Any-grade cancer
Age and PSA* 0.719 (0.672–0.767) 0.632 (0.590–0.674)
Age, four-kallikrein panel 0.777 (0.736–0.819) 0.683 (0.644–0.722)
Age, PSA, DRE* 0.736 (0.689–0.782) 0.638 (0.597–0.679)
Age, four-kallikrein panel, and DRE 0.784 (0.742–0.826) 0.690 (0.652–0.729)

AUC = area under the curve; DRE = digital rectal examination; PSA = prostate-specific antigen.

Data are shown as AUC (95% confidence interval). This risk model incorporates age and total PSA, a previously specified model using age and a panel of four kallikrein markers, and a second previously specified model using age, a panel of four kallikrein markers, and digital rectal examination.

*

AUC was corrected for overfit using 10-fold cross validation.